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Clinical relevance of peripheral vascular occlusive
disease in patients with rheumatoid arthritis and
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James C. Stanley, MD, Ann Arbor, Mich
Introduction: Peripheral vascular occlusive disease (PVOD) and rheumatologic disease (RD) are common in older
patients. The effect that coexistence of these diseases may have on patient health has not been rigorously investigated. The
present study was undertaken in an attempt to characterize patients with PVOD plus RD in terms of inflammatory
serologic disorders, medications, and procedures, and their relation to limb salvage.
Methods: Medical records were reviewed retrospectively for all patients with diagnosed coexistent PVOD and non-arteritis
RD treated over 15 years at the University of Michigan Hospital. Demographics, operative and medical therapies, and
serologic studies were analyzed. Univariate and multivariate analysis and the Kaplan-Meier method were used to assess
these variables in relation to limb salvage.
Results: Forty-one patients (34 women, 7 men), with mean age of 67 years, were studied. Mean antinuclear antibody titer
was 274, C-reactive protein concentration was 3.1 mg/mL, and sedimentation rate was 49. Twenty-nine percent of
patients had claudication, 49% had rest pain, and 32% had tissue loss. Mean ankle brachial index was 0.55. Medications
included nonsteroidal anti-inflammatory drugs (67% of patients), corticosteroids (54%), and specific immunosuppressive
agents (27%). Operative therapy included aortofemoral bypass grafting (n  4), infrainguinal bypass grafting (n  14),
embolectomy (n 4), and primary amputation (n 7). Overall 5-year limb salvage rate was 70% in patients undergoing
bypass surgery. Comparison of surgical with nonsurgical patients showed no significant differences in baseline risk
factors, serologic disorders, or anatomic location of vascular disease. Multivariate analysis revealed that rest pain and lack
of immunosuppression were significantly predictive of need for revascularization or amputation (P < .05).
Conclusion: Patients with RD should receive treatment on the basis of standard criteria for limb ischemia, in that surgical
revascularization outcomes are satisfactory. Immunosuppressive agents may confer a protective effect against progression
of PVOD. (J Vasc Surg 2003;38:111-5.)
Peripheral vascular occlusive disease (PVOD) is an in-
creasingly recognized manifestation of systemic atheroscle-
rosis.1 Recent investigations suggest markers of inflamma-
tion, eg, C-reactive proteins (CRP), correlate highly with
cardiac mortality and reflect the systemic inflammatory
nature of atherosclerosis.2-5 The relation between inflam-
matory rheumatologic disease (RD) and atherosclerotic
occlusive disease has recently been highlighted by the find-
ing that atherosclerosis progression may be accelerated in
patients with rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE).6-10
RD, like PVOD, exhibits increased incidence in elderly
patients, with diverse manifestations. Musculoskeletal
symptoms, particularly joint pain and stiffness, manifested
as arthritis are most common. Two common Rds, ie, RA
and SLE, are characterized by systemic inflammation, with
autoantibodies to various cell surface antigens. The under-
lying pathophysiologic disease is considered related to
dysfunctional regulation of T-cell immunity, perhaps by
common antigens and lack of clonal lymphocyte elimina-
tion.11,12 Disease severity ranges from mildly disabling to
life-threatening.
Few studies have examined the clinical course in pa-
tients with both PVOD and RD. Several reports have
focused on wound care strategies, because these patients
are predisposed to skin ulcerations and decreased ability to
heal, given the often powerful anti-inflammatory thera-
pies.13-15 Two small series reported macrovascular arterial
occlusive disease in several patients with SLE, with poor
graft patency and limb salvage.16-18 Inflammatory vascu-
litides, eg, giant cell arteritis, are a well- known subset of
RD, with resultant large artery obliteration, yet these enti-
ties are less common than either RA or SLE. Furthermore,
patients with inflammatory arteritis are usually young and
have few associated atherosclerotic risk factors. This likely
represents a disease process entirely different from typical
atherosclerotic occlusive disease that affects the elderly.
This study was undertaken to characterize the clinical
course of patients with PVOD and RD and to determine
the liklihood of limb loss after intervention compared with
no intervention. Certain standard risk factors for athero-
sclerosis and rheumatologic and inflammatory serologic
disorders were analyzed to determine the association be-
tween PVOD-RD that might progress to requiring surgery
versus stable PVOD.
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METHODS
Medical records were reviewed for all patients with a
diagnosis of PVOD plus RD who received treatment at the
University of Michigan Hospitals from 1985 to 2000.
Diagnoses were made with standard ICD-9-CM (Interna-
tional Classification of Disease, 9th revision, Clinical mod-
ification) codes, including 714.0 (RA), 710.0 (SLE), and
440.2 to 440.24 (PVOD). Patients with combined rheu-
matologic and venous insufficiency, upper extremity dis-
ease (2 patients over 15 years), or inflammatory arteritides
were excluded. Patient demographic characteristics, com-
mon atherosclerotic risk factors, antinuclear antibody
(ANA) titer, CRP level (not high sensitivity), and sedimen-
tation rate (Westergren method) were recorded. PVOD
presentation was defined as claudication, rest pain, and
ulcerative tissue loss. Medical therapies for RD included
nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin
(ASA), gold, and immunosuppressive agents (cyclosporin,
cyclophosphamide, azathioprine, FK506). Ankle-brachial
index (ABI) was recorded both before and after any proce-
dure. Disease was classified with arteriography as aortoiliac,
femoral and above-knee popliteal, or below-knee infra-
geniculate disease. Operative procedures included aorto-
femoral (proximal), femoral to above-knee popliteal, and
femoral to distal artery bypass grafting (distal revasculariza-
tion).19 Limb salvage and mortality were documented.
Because the operative procedures were mixed and patient
numbers were small, only limb salvage, not patency, was
determined. The University of Michigan Institutional Re-
view Board (2000-0821) approved the study. Follow-up
data were available for 39 of 41 patients.
Statistical analysis. Data were entered into an Excel
97 database (Microsoft, Redmond, Wash) and analyzed
with SAS version 8.2 (SAS Institute, Cary, NC). Descrip-
tive statistics were generated with summary tables for con-
tinuous data and frequency tables for dichotomous out-
comes. Because the major outcomes of interest were best
expressed as limb salvage rates for patients undergoing
procedures at different times and the number of subjects
was limited, the analysis was prepared with Kaplan-Meier
product-limit estimates from the PROC LIFETEST rou-
tine of the SAS program.19 Univariate analysis was per-
formed to evaluate the importance of covariates related to
operative versus nonoperative therapy. Covariates signifi-
cantly associated (P  .05) with the need for operative
therapy were entered into a SAS logistic regression model
with PROC LOGISTIC, and the covariates were assessed
to determine those that were independently associated with
the outcomes of interest.
RESULTS
Forty-one patients with both PVOD and RD com-
posed the study population (Table I). There were 34
women and 7 men, with mean age of 67 years. Thirty-one
patients had RA, and 10 patients had SLE.
Treatment of RD included corticosteroids (n 22),
NSAIDs (n  27), gold (n  5), and immunosuppressive
agents (n  11). No patient was given cyclooxygenase II
inhibitors. Concurrent disease included diabetes, hyperlip-
idemia, and coronary artery disease. Tobacco use was com-
mon. All serologic studies for RD yielded abnormal results,
compared with standard values at the University of Michi-
gan. Rest pain was the most common complaint (49%);
ulceration (32%) and claudication (29%) occurred less fre-
quently. Arteriographic images were available for 83% of
patients, and demonstrated aortoiliac disease in 22 patients,
femoral-popliteal disease in 20 patients, and infrageniculate
disease in 8 patients.
Twenty-nine patients underwent bypass grafting or
subsequent amputation, because of standard indications of
severe lifestyle- altering claudication (n 5), rest pain (n
18), and tissue loss (n 8). In comparison, 12 patients had
full limb salvage without operative intervention (n  9) or
required only partial foot amputation (minor amputa-
tion20; n  3). Of interest, of the patients who did not
undergo operative intervention, 5 patients had ulceration,
although average ABI was 0.73. Of these, 2 patients had
arteriographically confirmed aortoiliac disease. Operative
therapy included an aortofemoral bypass (n  4), femoral-
popliteal bypass (n 4), femoral-distal bypass (n 6), and
above-knee popliteal-distal artery bypass (n  1). Four
patients underwent separate arterial embolectomy because
of thromboembolic events that produced acute limb isch-
emia; limb salvage was successful in 3 of these patients.
Seven patients required amputation, because of failed infra-
Table I. Patient demographics
Average age (y) 67
Male/female ratio 7:34
Rheumatoid arthritis plus systemic lupus
erythematosus
31:10
Diabetes mellitus (%) 22
Tobacco use (%) 73
Hyperlipidemia (total cholesterol 220
mg/dL) (%)
27
Coronary artery disease (%) 46
Hypercoagulable state* (%) 5
Anti-nuclear antibody titer (nl 1:80)
(mean  SD)
274  607
C-reactive protein (nl 0.0-0.6) (mean  SD) 3.17  3.2
Sedimentation rate (Westergren method)
(nl 0-20) (mean  SD)
49  30
Rheumatoid factor (30 IU/dL) 391.0
Ankle-brachial index (mean) 0.55
Treatment
NSAIDs (%) 66
Steroid agents (%) 54
Gold (%) 12
Immunosuppressive agents (%) 27
Symptoms
Claudication (%) 29
Rest pain (%) 49
Ulcer (%) 32
Anatomic distribution
Aortoiliac artery 65
Femoral-popliteal artery 58
Infrageniculate artery 24
*Protein C, protein S, antithrombin III, factor V Leiden, prothrombin
20210A, anticardiolyn antibody.
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geniculate revascularization in 3 patients, an earlier failed
attempt at thrombolysis in 2 patients, and a failed attempt
at catheter embolectomy in 2 patients. Three patients had
wound complications from the surgery and required hos-
pitalization; none of these patients lost the limb. Patients
with wound complications treated on an outpatient basis
were not included.
Univariate analysis: Operative versus nonoperative
therapy. Comparisons were made with respect to standard
atherosclerotic risk factors, laboratory serologic values,
level of vascular disease, type of procedure, and need for
operation (Table II). Indications for admission were all
because of limb-related complaints, primarily associated
with PVOD. The distribution of SLE and RA was similar
between groups, as was frequency of comorbid atheroscle-
rotic risk factors. ANA titer tended to be higher in patients
who eventually underwent bypass grafting or amputation,
compared with ANA titer in patients who maintained limbs
without surgery (P  .06). Patients who did not undergo
surgery more frequently had an initial complaint of claudi-
cation (58% vs 17%; P  .02) compared with patients
requiring surgery. ABI was significantly lower, not unex-
pectedly, in patients who underwent surgery (P  .05). A
greater percentage of patients who received immunosup-
pressive agents did not subsequently undergo surgery (P
.052). Analysis of conduit type and other patient medica-
tions was not significant. Mean survival of study patients
was 81 6.7 months. However, those patients who had no
further operations because of PVOD had higher overall
mortality (42% vs 17%) at 42-month mean follow-up. Most
causes of death were noncardiovascular, including cancer
(n  4), cardiovascular (n  4), and mixed organ failure
(n  3).
Multivariate and Kaplan-Meier analyses. Logistic
regression provided a simplified model for predicting out-
come. A highly significant model (P  .004) determined
that patients using immunosuppressive drugs were 4.6-fold
less likely to require an operative intervention, whereas
presence of rest pain was strongly associated with the need
for operative intervention (Table III). Overall limb salvage
was 70% at 60 months (Figure). There were no differences
in limb salvage between patients with SLE or RA at 60
months.
DISCUSSION
This report documents clinical manifestations and out-
come of operative and nonoperative treatment of PVOD
and RD. This is the largest series reported to date, and the
results suggest that overall limb salvage and outcome after
operation are satisfactory compared with previous reports
of bypass grafting in patients without RD.21-23 In the
Table III. Multivariate analysis of factors related to
protection from operative therapy
Odds ratio
95% confidence
interval P*
Immunosuppression 4.6 0.9-24 .05
Rest pain 0.125 0.03-0.56 .02
*P  .004 for models together factors.
Table II. Comparisons between patients who did or did not undergo surgery
No surgery
Surgeryn %
Total (n) 12 29
Rheumatoid arthritis 3 25 7 24
Systemic lupus erythematosus 9 75 22 76
Diabetes mellitus 3 25 6 21
Coronary artery disease 7 58 12 41
Tobacco use 9 75 21 72
Hypercholesterolemia (220 mg/dL) 3 25 8 28
Antinuclear antibody titer (nl 1:80) (mean  SD) 40  113 418  740*
C-reactive protein (nl 0-0.06) (mean  SD) 1.9  1.6 4.0  3.8
Sedimentation rate (Westergren method) (nl 0-20)
(mean  SD)
41  30 53  31
Rheumatoid factor (30 IU/dL) 353 408
Ankle-brasheal index (mean) 0.75 0.46
Symptoms
Claudication 7 58 5 17
Rest pain 2 17 18 62*
Ulcer 5 17 8 27
Treatment
NSAIDs 9 75 18 62
Steroid agents 6 50 16 55
Gold 3 25 5 17
Immunosuppressive agents 6 50 5 17*
*P  .05.
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present series, demographics, risk factors, and indications
for vascular reconstruction were also similar to those in
reported series; ie, most bypass grafting was performed for
limb salvage. Diabetes was not so common as it is in many
PVOD bypass series, despite the frequent use of corticoste-
roid agents, which may unmask diabetes mellitus. Al-
though the present series is small and assumes that the need
for operative bypass or amputation implies more severe
PVOD, a highly significant correlation between progres-
sion to operation and patients not receiving immunosup-
pressive agents was found. This suggests, but by no means
proves, that diminution of the atherosclerotic occlusive
process with immunosuppressive agents may have oc-
curred. Similar findings were documented in a report by
DePalma et al,24 in which symptoms in patients with active
RD plus PVOD improved with high-dose corticosteroid
therapy. Further, they document that patients with active
RD and PVOD have worse outcome than do those with
limb manifestations, eg, infection, from either vasculitis or
primarily RD. It was not possible from this study to ascer-
tain the severity of RD at admission because of limb-related
complaints.
The inflammatory nature of atherosclerosis is well es-
tablished from animal models and epidemiologic stud-
ies.3-5 Atherosclerotic pathogenesis seems to involve mac-
rophages and lymphocytes, directing inflammation and
remodeling of the affected arteries. Mechanisms whereby
immunosuppressive agents may impair atherosclerosis in-
clude T-cell inhibition, inhibition of growth factor release
from macrophages, and direct inhibition of smooth muscle
cell proliferation. Of interest, corticosteroid use, which
impairs many inflammatory cellular functions, was not pro-
tective. However, corticosteroid agents increase cholesterol
levels, which may have counteracted their potential protec-
tive actions. It is intriguing to consider, with recent studies
documenting efficacy of sirolimus-coated stents in prevent-
ing recurrent stenosis after angioplasty,25 as well as experi-
mental data that show that immunosuppressive agents in-
hibit neointimal hyperplasia,26 that the lymphocyte may be
a significant contributor to atherosclerosis. Other reports
have strengthened the role of the lymphocyte in atheroscle-
rosis progression.27,28
Rest pain was also significantly associated with need for
surgery. Operative therapy was used judiciously in this
group of patients. ABI, as well as symptoms in patients who
underwent surgery compared with those who did not,
support this bias. Of interest, nearly equal numbers of
patients in the operative and nonoperative groups had
ulcerations. However, ulceration was not associated with
need for operation. This is likely because of the increased
frequency of skin lesions and ulcerations in patients with
RD that are not ischemic in origin.13-15 Healing of these
lesions often occurs with good wound care if the blood
supply is adequate. Therefore vascular reconstruction
should be offered based on severity of ischemia, distinct
from skin ulceration. It does not seem to be the case, as
with diabetes, that nearly normal perfusion is needed to
heal ulcers in these patients.23,24
Autoimmune mechanisms are considered the underly-
ing mechanism in the genesis of RD and was the reason for
grouping SLE and RA together.11,12 It was not surprising
that CRP was elevated in our patients, but further investi-
gation may be warranted as to whether elevated ANA titer
may be a marker of aggressive vascular disease progression.
Inasmuch as atherosclerosis is also associated with systemic
inflammation, a common mechanism may be present in
these patients. However, few surgical bypass series analyze
the coexistence of RD as a risk factor for poor outcome.
These earlier reports and our experience suggest the con-
vergent nature of thrombosis and inflammation. In contrast
to previous reports concerning this patient population, it
was surprising that the limb salvage rate was as high as
70%.16,17 Also surprising was lack of postoperative wound
complications requiring hospitalization, especially in the
setting of significant corticosteroid use. Careful postopera-
tive care, including knowledge of increased risk for infec-
tion, may have contributed; however, it is also possible that
patients undergoing outpatient therapy were missed.
Amputation was performed in 6 patients, 3 of whom
had unsalvageable limbs because of ascending gangrene. As
the number of patients was small, no factors were found to
correlate statistically with limb loss or graft failure, and
primary and secondary graft patency was not evaluated. Of
no surprise, all amputations occurred after infrainguinal
reconstruction failure. Inflow procedures and embolec-
tomy were associated with 100% limb salvage at mean
follow-up of 45 months, similar to what would be expected
in patients without RD. Although antiphospholipid syn-
drome has been correlated with SLE29,30 and hypercoagu-
lability, this syndrome was not common among our pa-
tients. However, this may represent a lack of routine
assaying for it.
Limitations of the present study include the small co-
hort examined; lack of a concomitant control group of
patients without RD; and the dynamic nature of RD, which
may not be well captured, particularly with a retrospective
review of laboratory serologic data. Furthermore, the small
Kaplan-Meier life table shows overall limb salvage in 25 patients
who underwent vascular reconstruction.
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patient number limits the subgroup procedural-type anal-
ysis comparison between the various vascular surgical pro-
cedures reviewed, and these procedures are not entirely
equivalent in terms of outcome. However, it is the largest
series to date to evaluate this constellation of diseases. It is
recommended that patients with RD with PVOD disease
should receive the same treatment as for any patient with
the same symptoms or signs, with confidence that a vascular
surgical intervention will likely have a salutary outcome. In
addition, this report does not seek to change the indications
for peripheral interventions in patients with PVOD and
RD, but supports those already in place for patients with
PVOD only. Though intriguing, we cannot recommend
the use of immunosuppressive agents in patients with RD
and PVOD before further prospective clinical investigation,
because the side effects of many of these agents are hazard-
ous. However, patients with rest pain may be the best
group to study.
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